{"disease":{"id":"indication-2","name":"Indication 2","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":3,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"pf-07853578","indication_name":"Indication 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-07853578","generic_name":"pf-07853578","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"[specific protein]","drug_class":"Small molecule inhibitor","quality_score":22,"revenue":null,"mechanism":""},{"drug_id":"treatment-c","indication_name":"Indication 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Treatment C","generic_name":"treatment-c","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"met233-and-met097","indication_name":"Indication 2","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"MET233 and MET097","generic_name":"met233-and-met097","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":22,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05266404","title":"Phase 1 Bioequivalence Study of Dapagliflozin/Sitagliptin FDC vs Loose Combination of Single Components","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":46,"lead_sponsor_name":"AstraZeneca","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}